Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

By V. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K. Ellis, O. Salvado, C. Szoeke, S. Macaulay, Ralph M. Martins, P. Maruff and 3 more. Lancet Neurology, 2013

1,951 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/1525814d7af052e061727680d46d4d4982ffc641

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Reisa A. Sperling
2. D. Selkoe
3. Bruno Dubois
4. G. Bu
5. L. Mucke

In Physiology

1. Reisa A. Sperling
2. José Luis Molinuevo
3. William J. Jagust
4. John Hardy
5. Philip Scheltens
6. Perminder S. Sachdev
7. Gil D. Rabinovici
8. Suzanne L. Baker

In Psychiatry and Mental health

1. Philip Scheltens
2. Perminder S. Sachdev
3. William J. Jagust
4. Michelle M. Mielke
5. John Hardy
6. Reisa A. Sperling
7. José Luis Molinuevo
8. Gaël Chételat

Citations in the corpus

• 2016 Alzheimer's disease facts and figures (2016, positive): “This proposed preclinical or presymptomatic stage reflects current thinking that Alzheimer’s-related brain changes may begin 20 years or more before symptoms occur [18-20].”
• Identification of pre-clinical Alzheimer’s disease by a profile of pathogenic proteins in neurally-derived blood exosomes: a case-control study (2014, background): “Increases in brain tissue oligomeric amyloid b (Ab) peptides and phosphorylated tau (P-tau) detected by central nervous system (CNS) imaging and in cerebrospinal fluid (CSF) levels of soluble Ab1–42 and P-tau have been documented years before the signs of AD [3–6].”
• 2020 Alzheimer's disease facts and figures (2020, methodology): “org/trajectory: (1) cost data from the 2011MedicareCurrent Beneficiary Survey (MCBS) were used rather than data from the 2008MCBS; (2) prevalence among older adults was assumed to equal the prevalence levels from Hebert and colleagues62 and included in this report (5.”
• A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease (2014, background): “The development of Alzheimer’s disease (AD), the most common cause of dementia, is slow and progressive with a presymptomatic course over several years to decades [2,3].”